Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18111982 | 0.86 | LMNA (0.39) | MAPK1LMNAHTTHDAC1PARP1 | |
| SCHEMBL16371471 | 0.86 | LMNA (0.39) | MAPK1LMNAHTTHDAC1PARP1 | |
| SCHEMBL7081533 | 0.82 | PARP1 (0.57) | MAPK1LMNAHDAC1POLBPARP1 | |
| SCHEMBL3434229 | 0.81 | SIRT2 (0.44) | MAPK1LMNAHTTKMT2ASIRT2 | |
| SCHEMBL5495641 | 0.80 | MCHR1 (0.46) | LMNAPOLBKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL9142672 | 0.79 | CHRNA7 (0.45) | LMNAHTTPOLBPARP1KMT2A | |
| SCHEMBL5495222 | 0.79 | SIGMAR1 (0.42) | HDAC1JAK2JAK1SIGMAR1 | |
| SCHEMBL9142665 | 0.79 | CHRNA7 (0.45) | LMNAHTTPOLBPARP1KMT2A | |
| SCHEMBL9142677 | 0.79 | CHRNA7 (0.45) | LMNAHTTPOLBPARP1KMT2A | |
| SCHEMBL4506882 | 0.78 | HDAC1 (0.51) | HDAC1SIRT1JAK2JAK1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560460-B2 | Substituted piperazines and methods of use | AMGEN INC. (US) | 2009-07-14 | — | — | US | disclosed |
| EP-1417190-B1 | SUBSTITUTED PIPERAZINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEN INC (US) | 2008-10-22 | — | — | EP | disclosed |
| US-20070265248-A1 | Substituted piperazines and methods of use | AMGEN INC. (US) | 2007-11-15 | — | — | US | disclosed |
| EP-1757608-A1 | New benzazepine derivatives, medicaments containing the same and their use in the preparation of medicaments | Sanochemia Pharmazeutika Aktiengesellschaft (AT) | 2007-02-28 | — | — | EP | disclosed |
| US-7115607-B2 | Substituted piperazinyl amides and methods of use | AMGEN INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-7101890-B2 | Benzazepine derivatives, drugs containing these and use of the same for producing drugs | SANOCHEMIA LTD. (MT) | 2006-09-05 | — | — | US | disclosed |
| US-20040067974-A1 | New benzazepine derivatives, drugs containing these and use of the same for producing drugs | SANOCHEMIA LTD. (MT) | 2004-04-08 | — | — | US | disclosed |
| US-20030220324-A1 | Substituted piperazines and methods of use | AMGEN INC. | 2003-11-27 | — | — | US | disclosed |
| US-6638925-B2 | In particular benzofuro(3a,3,2,ef)(2)benzazepin; treatment of Alzheimer's disease and related dementia conditions, Langdon-Down syndrome | SANOCHEMIA LTD. (MT) | 2003-10-28 | — | — | US | disclosed |
| US-20030092700-A1 | BENZAZEPINE DERIVATIVES, MEDICAMENTS CONTAINING THE SAME AND THEIR USE TO PREPARE MEDICAMENTS | SANOCHEMIA LTD. (MT) | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220324-A1 | Substituted piperazines and methods of use | MC5R, MC4R, MC1R | MAPK1 2191/4885LMNA 3009/4885HTT 497/4885 |
| US-20030092700-A1 | BENZAZEPINE DERIVATIVES, MEDICAMENTS CONTAINING THE SAME AND THEIR USE TO PREPARE MEDICAMENTS | PSEN2, BACE2, BACE1 | MAPK1 3526/4885LMNA 270/4885HTT 1559/4885 |
| US-20070265248-A1 | Substituted piperazines and methods of use | MC5R, MC4R, MC1R | MAPK1 2191/4885LMNA 3009/4885HTT 497/4885 |
| US-20040067974-A1 | New benzazepine derivatives, drugs containing these and use of the same for producing drugs | BACE2, PSEN2, BACE1 | MAPK1 3452/4885LMNA 386/4885HTT 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.